UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 123

Sortiert nach

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2018-10, Vol.32 (5), p.481-497

2018

Link zum Volltext

Verfügbarkeit prüfen

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

Frontiers in immunology, 2022-05, Vol.13, p.752065-752065

2022

Link zum Volltext

Verfügbarkeit prüfen

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Communications biology, 2021-06, Vol.4 (1), p.699-699, Article 699

2021

Link zum Volltext

Verfügbarkeit prüfen

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Molecular cancer therapeutics, 2019-06, Vol.18 (6), p.1081-1091

2019

Link zum Volltext

Verfügbarkeit prüfen

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy

Medicine in drug discovery, 2020-12, Vol.8, p.100073, Article 100073

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay

Molecules (Basel, Switzerland), 2011-08, Vol.16 (9), p.7344-7356

2011

Link zum Volltext

Verfügbarkeit prüfen

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

Cancers, 2023-04, Vol.15 (8), p.2263

2023

Link zum Volltext

Verfügbarkeit prüfen

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34 + Stem/Progenitor Cells

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1497-1510

2017

Link zum Volltext

Verfügbarkeit prüfen

P740: PK, PD AND SAFETY OF FIRST‐IN‐HUMAN, FIRST‐IN‐CLASS PHASE I TRIAL (AUR103‐101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

HemaSphere, 2023-08, Vol.7 (S3), p.e183727f-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

European journal of medicinal chemistry, 2014-09, Vol.84, p.382-394

2014

Link zum Volltext

Verfügbarkeit prüfen

Anti-Programed Cell Death Ligand 1 Peptide Improves Survival in Sepsis

The Journal of surgical research, 2016-09, Vol.208, p.33-39

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors

ACS medicinal chemistry letters, 2013-12, Vol.4 (12), p.1152-1157

2013

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-L1 peptide improves survival in sepsis

The Journal of surgical research, 2017-02, Vol.208, p.33-39

2017

Link zum Volltext

Verfügbarkeit prüfen

27346 Efficacy and safety from a phase II study of AUR101, a RORγ inhibitor in moderate-to-severe psoriasis (INDUS-2)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB136-AB136

2021

Link zum Volltext

Verfügbarkeit prüfen

An oncolytic adenovirus expressing soluble transforming growth factor-β type II receptor for targeting breast cancer: in vitro evaluation

Molecular cancer therapeutics, 2006-02, Vol.5 (2), p.367-373

2006

Link zum Volltext

Verfügbarkeit prüfen

Small-molecule antagonists of the immune checkpoint pathways: concept to clinic

Future medicinal chemistry, 2017-08, Vol.9 (12), p.1305-1308

2017

Link zum Volltext

Verfügbarkeit prüfen

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.28-38

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1713: Novel, potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1713-1713

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4148: An orally bioavailable small molecule antagonist of TIM-3 signaling pathway shows potent anti-tumor activity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4148-4148

2019

Link zum Volltext

Verfügbarkeit prüfen

Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents

Cancer gene therapy, 2005-08, Vol.12 (8), p.691-698

2005

Link zum Volltext

Verfügbarkeit prüfen

Ternary complex formation of AFN‐1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies

Chemical biology & drug design, 2020-08, Vol.96 (2), p.704-713

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(120)

Publikationsform

Artikel
(122)
Tagungsberichte
(1)

Sprache

Englisch
(123)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy

Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34 + Stem/Progenitor Cells

P740: PK, PD AND SAFETY OF FIRST‐IN‐HUMAN, FIRST‐IN‐CLASS PHASE I TRIAL (AUR103‐101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

Anti-Programed Cell Death Ligand 1 Peptide Improves Survival in Sepsis

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors

Anti-PD-L1 peptide improves survival in sepsis

27346 Efficacy and safety from a phase II study of AUR101, a RORγ inhibitor in moderate-to-severe psoriasis (INDUS-2)

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

An oncolytic adenovirus expressing soluble transforming growth factor-β type II receptor for targeting breast cancer: in vitro evaluation

Small-molecule antagonists of the immune checkpoint pathways: concept to clinic

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Abstract 1713: Novel, potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Abstract 4148: An orally bioavailable small molecule antagonist of TIM-3 signaling pathway shows potent anti-tumor activity

Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents

Ternary complex formation of AFN‐1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations

Suchergebnisse filtern